Merck exceeded its full-year EPS guidance and reported strong sales growth in key areas like KEYTRUDA and vaccines, despite some headwinds from defense contract delays. Management's positive outlook and solid 2017 guidance are likely to bolster investor confidence. These factors suggest a favorable short-term impact on the stock.

[1]